The board of directors of Immune Response Corp. has adopteda stockholder rights plan designed to prevent a hostiletakeover. The plan, which the San Diego company said was notin response to any overture, would be triggered by an investoracquiring 15 percent of shares outstanding. Stockholders wouldreceive rights to buy shares of preferred stock at a substantialdiscount. Immune Response (NASDAQ:IMNR), which isdeveloping treatments for AIDS and autoimmune diseases,closed at $29.50, down 13 cents, on Friday.
(c) 1997 American Health Consultants. All rights reserved.